Lyell Immunopharma Profit Margin

The latest profit margin for LYEL is -920285.19% as of June 2026. That compares with -552328.33% in the prior-year period — down 66.6% year over year. That is below the Healthcare sector average of 13.45%. Investors often review this figure alongside Lyell Immunopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, LYEL's profit margin moved from -552328.33% to -920285.19% — a 66.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lyell Immunopharma's valuation or profitability profile.

Against Healthcare companies, LYEL currently prints -920285.19% for profit margin, while the sector average sits near 13.45%. That is roughly 6843493.1% below the sector mean. Large gaps often invite a closer look at Lyell Immunopharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Lyell Immunopharma converts resources into returns. At -920285.19%, LYEL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -552328.33% in the prior-year period — down 66.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LYEL's profit margin (-920285.19%), review year-over-year change from -552328.33%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.